Specialty drugs are devouring employers' health care spend, with costs rising faster than inflation year after year. Often, these pharmaceutical therapies aren't just another line item – they're the single largest cost driver.
There is a proven way to curb these costs dramatically without compromising care for employees with complex, chronic conditions. But too often, this option is left on the table.
Biosimilars, which are in most cases a far more affordable – and clinically equivalent – alternative to brand-name biologics, are a solution that could save employers millions and lower the total cost of care, yet they remain vastly underutilized. At the heart of the problem is a rebate-driven pharmacy ecosystem that rewards higher costs over actual value.
In this upside-down system, the "discount" from rebates can make wildly expensive drugs look superficially competitive, while more affordable and equally clinically effective drugs – including biosimilars – are sidelined. This distortion keeps employers and their employees from appreciating the full benefits of choosing certain drugs, such as biosimilars.
For advisors and employers that have begun to adopt biosimilars in their benefit designs, this rebate system is why biosimilars can sometimes appear to be cost neutral at first glance – despite the fact they are priced about 50% lower than their brand-name alternatives. But those savings will compound over time as competition increases, adoption grows, and market dynamics shift. With nearly 120 biologics projected to lose patent protection in the next decade, advisors and employers that begin adopting biosimilars now can capture meaningful near-term savings while positioning themselves for exponential cost reductions in years to come.
The opportunity for employers and advisors that take the proactive approach to specialty drug spend is clear: lock in meaningful upfront savings by embracing biosimilars today, and set the stage for even greater cost reductions when more come to market tomorrow.
Skepticism about biosimilars mirrors a trend we've seen before. When generic drugs were first introduced, many patients and physicians worried they were less effective simply because they cost less. Over time, education and trust helped generics become a cornerstone of cost containment. Today, generics make up 90% of prescriptions in the U.S. while driving only a fraction of total prescription spending.
Advisors and employers are uniquely positioned to lead the biosimilar adoption curve, gaining the advantage of early action before the rest of the market inevitably follows. By demanding transparency, rejecting rebate-first contracts, and making biosimilars the default choice, they can rewrite the rules of the system.
Other countries have already proven this system can work. In Europe, where incentives are structured to reward value over rebates and where national policies encourage affordable alternatives to high-cost brand-name drugs, biosimilars are much more widely accessible – and have brought costs down significantly while demonstrating clinical value. The U.S. has been slower to adopt, not because the science is lacking, but because the infrastructure to incentivize biosimilar adoption is altogether missing. Here, lucrative rebate checks tip the scale in favor of higher-cost brand drugs.
With the help of an advisor, employers have more than purchasing power for their teams – they have the opportunity to drive down drug costs, expand access to life-changing therapeutics, and spark meaningful transformation in our pharmacy – and health care – system. They can work with health plans and pharmacy partners to build benefit designs that make the most affordable, clinically effective drugs the default choice. They can press their partners to provide cost transparency instead of rebate figures that obscure actual prices.
Perhaps most importantly, they have an opportunity to set an expectation that people deserve access to safe, effective, and more affordable alternatives to the drugs they need to live comfortably day-to-day.
If hesitation persists, drug costs will keep climbing, swallowing up dollars that could be invested elsewhere. But that future doesn't need to be certain. Advisors and employers that embrace biosimilars now can take the first step toward turning one of the fastest-growing cost drivers in health care into one of the biggest opportunities for cost savings.
This is much more than just smart benefit design. It's a chance for advisors and employers to spark the kind of market shift that has already reshaped other corners of the health care industry – the kind of market shift that can lower costs, increase access, and force an outdated system to finally prioritize value over anything else.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.